科研动态期刊摘要
[评论] 小分子GLP-1受体激动剂奥福格列普隆在2型糖尿病中的心血管安全性确立
The Lancet · 2026-10-16 12:08
摘要
GLP-1受体激动剂的心血管结局试验，迄今为止主要包含肠促胰岛素激素GLP-1的肽类似物，已从最初主要设计用于确立心血管安全性的研究，发展为证明心血管获益的试验。1–3 多种皮下给药的GLP-1受体激动剂已显示可显著降低主要不良心血管事件（MACE）并提供肾脏保护，1–3 最近口服司美格鲁肽也显示出类似获益。
English
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes
Cardiovascular outcomes trials with GLP-1 receptor agonists, which to date have largely comprised peptide analogues of the incretin hormone GLP-1, have evolved from studies primarily designed to establish cardiovascular safety to trials demonstrating cardiovascular benefit.1–3 Substantial reductions in major adverse cardiovascular events (MACE) and kidney protection have been demonstrated with multiple GLP-1 receptor agonists for subcutaneous administration,1–3 and, more recently, with oral semaglutide.